Advanced Search

 

Study ID Status Title Patient Level Data
29060/704 Completed A Randomized, Multi-center, 10-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Obsessive Compulsive Disorder Study Listed on ClinicalStudyDataRequest.com
29060/711 Completed A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689 Study Listed on ClinicalStudyDataRequest.com
29060/715 Completed A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression Study Listed on ClinicalStudyDataRequest.com
29060/716 Completed A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD) Study Listed on ClinicalStudyDataRequest.com
29060/717 Completed A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Study Listed on ClinicalStudyDataRequest.com
29060/785 Completed A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety Study Listed on ClinicalStudyDataRequest.com
29060/810 Completed A double-blind, placebo-controlled, 3-arm, fixed-dose study of 12.5 mg/day and 25mg/day Paroxetine CR in the treatment of Major Depression. Study Listed on ClinicalStudyDataRequest.com
29060/874 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed with Major Depressive Disorder Study Listed on ClinicalStudyDataRequest.com
29060/877 Completed An open labeled, single sequence study to investigate the safety and pharmacokinetics of oral pimozide when co-administered with repeat dosing oral paroxetine 60 mg od in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
3065A1-115 Completed Pharmacokinetics of Retigabine and its N-Acetylated Metabolite (NAMR) and the Impact on Serum Bilirubin in Subjects with Different Genotypes for UDP-glucuronyl transferase 1A1 (UGT1A1) and N-acetyl transferase (NAT2) Study Listed on ClinicalStudyDataRequest.com
3065A1-117 Completed Tolerability of intravenous dose titration of retigabine administered as short time infusion in healthy male volunteers Study Listed on ClinicalStudyDataRequest.com
3065A1-123 Completed Absolute and Relative Bioavailability of Retigabine IR capsules in Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
3065A1-205 Completed A Randomized, Double-blind, Placebo-controlled, Parallel group, Multicenter, Dose-ranging, Efficacy and Safety Study of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients With Partial Epilepsy Study Listed on ClinicalStudyDataRequest.com
3065A1-208 Completed A multicenter, open-label, long-term, safety tolerability, and efficacy study of GKE-841 (retigabine D-23129) in adult patients with epilepsy (extension of study 202) Study Listed on ClinicalStudyDataRequest.com
3065A1-212 Completed A multicenter, open-label, long-term, safety tolerability, and efficacy study of retigabine in adult patients with epilepsy (extension of study 205) Study Listed on ClinicalStudyDataRequest.com
3065A1-214 Completed A Randomized, Double-Blind, Parallel-Group, Exploratory Safety and Tolerability Study of 3 Titration Rates of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients with Refractory Partial Epilepsy Study Listed on ClinicalStudyDataRequest.com
3065A1-216 Completed A Multicenter, Open-Label, Long-Term Extension, Safety and Tolerability Study of Retigabine (GKE-841) in Adult Patients with Epilepsy Study Listed on ClinicalStudyDataRequest.com
347414/008 Completed Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age Study Listed on ClinicalStudyDataRequest.com
347414/010 Terminated Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life. Study Listed on ClinicalStudyDataRequest.com
347414/016 Completed A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine Study Listed on ClinicalStudyDataRequest.com
347414/020 Completed A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™(Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8–16 Weeks of age Study Listed on ClinicalStudyDataRequest.com
347414/023 Completed A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age. Study Listed on ClinicalStudyDataRequest.com
347414/026 Completed A Phase III, randomized single-blind clinical trial to assess the immune memory induced by an investigational vaccination regimen in comparison with Prevnar and the immune response to a fourth dose of the pneumococcal vaccine and the investigational vaccination regimen, when admininistered to healthy children (12-15 Months) Study Listed on ClinicalStudyDataRequest.com
347414/028 Completed A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SmithKline Beecham Biologicals' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old Study Listed on ClinicalStudyDataRequest.com
347414/036 Completed A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals’ investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023 Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.